These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22576690)

  • 1. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer.
    Yang J; Ahn S; Wu Z; Hwang DJ; Miller DD; Dalton JT
    Int J Oncol; 2012 Jul; 41(1):337-44. PubMed ID: 22576690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
    Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
    Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer.
    Musende AG; Eberding A; Wood CA; Adomat H; Fazli L; Hurtado-Coll A; Jia W; Bally MB; Tomlinson Guns ES
    Anticancer Drugs; 2012 Jun; 23(5):543-52. PubMed ID: 22481061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
    Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
    Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
    Han JM; Myung H; Kim S
    Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles.
    Li CM; Lu Y; Narayanan R; Miller DD; Dalton JT
    Drug Metab Dispos; 2010 Nov; 38(11):2032-9. PubMed ID: 20675405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01.
    Kurata N; Kuwabara T; Tanii H; Fuse E; Akiyama T; Akinaga S; Kobayashi H; Yamaguchi K; Kobayashi S
    Cancer Chemother Pharmacol; 1999; 44(1):12-8. PubMed ID: 10367744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride].
    Wang CX; Li CL; Zhao X; Yang HY; Wei N; Li YH; Zhang L; Zhang L
    Yao Xue Xue Bao; 2010 Dec; 45(12):1565-9. PubMed ID: 21351498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
    Chun AW; Cosenza SC; Taft DR; Maniar M
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
    J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice.
    Fan A; Wei J; Yang M; Zhang Q; Zhang Y; Liu Q; Li N; Zhao D; Lu Y; Li J; Zhao J; Deng S; Zhang B; Zhu H; Chen X
    Eur J Pharm Sci; 2018 Aug; 121():74-84. PubMed ID: 29772274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer.
    Jiang J; Loganathan J; Eliaz I; Terry C; Sandusky GE; Sliva D
    Int J Oncol; 2012 May; 40(5):1339-44. PubMed ID: 22293856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
    Musende AG; Eberding A; Wood C; Adomat H; Fazli L; Hurtado-Coll A; Jia W; Bally MB; Guns ET
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1085-95. PubMed ID: 19301006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, biodistribution and metabolism of a novel selective androgen receptor modulator designed for prostate cancer imaging.
    Yang J; Wu Z; Wu D; Darby MV; Hong SS; Miller DD; Dalton JT
    Int J Oncol; 2010 Jan; 36(1):213-22. PubMed ID: 19956850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.